Any hopes of differentiation could come down to side effects.

Meanwhile, Pfizer reckons it's found the right dose for its KAT6.

The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.

TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.

Conference activity picks up, with the big one – ASCO – at the end of the month.

Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.

But sasanlimab's use looks set to remain narrow.

The company is stepping back in second-line breast cancer.

At long last luvelta-T is shelved, and Sutro seeks a new focus.

The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.